Tirzepatide vs. Semaglutide in Miami: Physician’s Guide

Tirzepatide and semaglutide are the two dominant incretin-based medications reshaping the management of type 2 diabetes and obesity. They share a mechanism—GLP-1 receptor agonism—but differ in molecular design, efficacy, and side-effect profile. Tirzepatide adds GIP receptor activity, producing greater average weight loss in head-to-head clinical trials. At TrufaMED in Surfside, these medications are prescribed only within a physician-led, fully evaluated medical weight management program—never as a retail product.

How GLP-1 and GIP Medications Work

Glucagon-like peptide-1 (GLP-1) is a gut hormone released in response to food intake. It slows gastric emptying, stimulates glucose-dependent insulin secretion, suppresses glucagon, and signals satiety to the hypothalamus. Glucose-dependent insulinotropic polypeptide (GIP) is a related incretin with complementary effects on insulin release and adipose tissue biology.

Semaglutide (brand names Ozempic, Wegovy) is a long-acting GLP-1 receptor agonist. Tirzepatide (brand names Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist—engineered to activate both receptor families in a single molecule.

Efficacy: What the Trials Show

In the SURMOUNT-1 trial, tirzepatide at the highest maintenance dose produced mean weight loss of approximately 20–22% at 72 weeks in adults with obesity without diabetes. In the STEP trials, semaglutide 2.4 mg weekly produced mean weight loss of approximately 14–15% at 68 weeks. Head-to-head data from SURMOUNT-5 has shown tirzepatide produces greater average weight loss than semaglutide when compared directly. (See: Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity, NEJM 2022, and Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM 2021.)

Both medications also improve glycemic control, blood pressure, triglycerides, and—in the SELECT trial for semaglutide—cardiovascular event rates in adults with established cardiovascular disease and obesity without diabetes.

Semaglutide (Wegovy) Doses

Wegovy is titrated slowly to minimize gastrointestinal side effects. The standard escalation is:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Ozempic (same active ingredient, diabetes labeling) is titrated to 0.5, 1.0, or 2.0 mg weekly.

Tirzepatide (Zepbound) Doses

Zepbound follows a similar titration:

• Weeks 1–4: 2.5 mg once weekly
• Weeks 5–8: 5 mg once weekly
• Target maintenance: 5, 10, or 15 mg weekly depending on response and tolerance

Dose selection is clinical. Higher doses produce greater weight loss on average but also greater rates of GI side effects. A skilled clinician titrates to the lowest dose that produces durable results.

Side Effects

The most common side effects of both tirzepatide and semaglutide are gastrointestinal:

• Nausea (especially during titration)
• Vomiting
• Diarrhea or constipation
• Abdominal discomfort, reflux
• Decreased appetite (clinically desired, occasionally excessive)

Less common but clinically important:

• Gallbladder events (cholelithiasis, cholecystitis) with rapid weight loss
• Pancreatitis (rare)
• Hypoglycemia (uncommon as monotherapy; increased when combined with sulfonylureas or insulin)
• Injection site reactions
• Loss of lean muscle mass during rapid weight loss—addressed through resistance training and adequate protein intake

Both medications carry a boxed warning regarding thyroid C-cell tumors observed in rodents. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

How TrufaMED Approaches Medical Weight Management

TrufaMED offers GLP-1 and dual-agonist therapy only within a supervised physician-led program. That means:

1. A comprehensive physician consult—medical history, medications, personal and family cancer history, cardiovascular status, and goals
2. Baseline laboratory evaluation including thyroid studies, metabolic panel, lipids, hemoglobin A1c, and vitamin status
3. A structured titration plan with scheduled follow-up
4. Nutrition and resistance-training guidance to preserve lean mass
5. Adjunctive IV support when clinically appropriate—our Slim & Trim IV ($250 in-clinic, $300 mobile) is a lipotropic/B-complex drip used alongside medical weight management to support energy and metabolic function
6. Exit planning—every patient has a strategy for de-escalation or maintenance rather than indefinite dose escalation

Medical weight management at TrufaMED is a concierge medicine service integrated with our broader preventive and metabolic programs.

Who Is a Candidate?

• BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea)
• No personal or family history of medullary thyroid carcinoma or MEN 2
• No active pancreatitis or severe gastroparesis
• Not currently pregnant or planning near-term pregnancy
• Willing to participate in nutrition, activity, and follow-up components of the program

Cost and Access

Pricing for GLP-1 and tirzepatide therapy varies with insurance coverage, pharmacy source, and dose. At TrufaMED we provide transparent program pricing at consult and work with each patient to identify the most appropriate sourcing strategy. Program components include the physician consult, laboratory work, medication prescription, structured follow-up, and adjunctive IV support as indicated.

Schedule Your Medical Weight Management Consult

If you are evaluating tirzepatide or semaglutide, the first step is a proper medical workup—not a prescription. Call (305) 537-6396 or book online to schedule a physician consult at TrufaMED.

Frequently Asked Questions

Is tirzepatide more effective than semaglutide?

On average, tirzepatide produces greater weight loss than semaglutide in clinical trials. Individual response varies, and the most effective medication is the one a patient tolerates and can sustain under physician supervision.

What are the most common side effects?

Gastrointestinal: nausea, vomiting, diarrhea or constipation, and abdominal discomfort—most pronounced during titration. Slow titration and dietary adjustments reduce severity.

What is the Wegovy dose schedule?

Wegovy titrates from 0.25 mg weekly at initiation through 0.5, 1.0, and 1.7 mg at four-week intervals, reaching 2.4 mg weekly maintenance by approximately week 17.

How long do I stay on tirzepatide or semaglutide?

Duration is individualized. Some patients transition to a maintenance dose after reaching goal weight; others taper under supervision. Abrupt discontinuation frequently leads to weight regain, which is why a planned maintenance strategy is part of every TrufaMED program.

Will I lose muscle on these medications?

Rapid weight loss from any cause can reduce lean mass. Resistance training, adequate protein intake (1.2–1.6 g/kg/day for most patients), and appropriate micronutrient support mitigate this. TrufaMED builds these elements into every program.

Is medical weight management covered by insurance?

Coverage for the medication itself depends on the patient’s plan and the indication. The TrufaMED concierge program components (consult, follow-up, IV support) are offered as elective services.